🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT05561504
Recruiting Observational

Helicobacter Pylori Local Prevalence and Antibiotic Resistance

NCT05561504 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2021-03-31
Last updated
2023-11-30

Condition(s) studied

Helicobacter Pylori InfectionHelicobacter Pylori GastritisDrug Resistant Bacterial InfectionAntibiotic Resistant InfectionGastric CancerMicrobial Colonization

Study summary

The clinical management of H. pylori infection depends essentially on two factors, prevalence and local resistance. In Germany, only limited data from rather small cohorts currently exist regarding both factors. Knowledge of the current prevalence (accounting for socioeconomic factors and age) is important for the selection of suitable detection methods, as this influences the positive and negative predictive value of the respective diagnostic methods. Current data on antibiotic resistance are essential for efficient therapy. In this clinical study, we will collect data on the frequency and severity of H. pylori infections and then, after endoscopic examination, on antibiotic resistance. Knowledge of the resistance situation is necessary for the selection of suitable therapeutic regimens. Furthermore, molecular methods for resistance detection are to be compared with conventional microbiological methods in order to be able to detect resistance more quickly. Furthermore, we aim to identify specific parameters for early detection of patients at particularly high risk of gastric cancer or with precancerous lesions due to infection. The aim is to identify carcinogenesis-relevant factors such as gastric microbiome signatures that will make it possible to identify patients who are most likely to benefit from prophylactic eradication therapy in terms of risk stratification.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Minimum age of 18 years * informed consent for HelicoPTER study * informed consent for HEPY biobank Exclusion Criteria: * no capacity to consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Medicine II, University Hospital of Munich Munich Germany Recruiting

More Technical University of Munich trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05561504 on ClinicalTrials.gov ↗ ← All trials in Germany